Can a home program help kids with sickle cell hit milestones?
NCT ID NCT06562439
First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time
Summary
This trial tests a home-based program called the Sickle Cell Caregiver Collaboration for Child Development (SCCCD) for infants and toddlers with sickle cell disease. The program combines a parenting curriculum with occupational therapy to help families support their child's learning and development. Researchers will measure developmental progress at 9, 18, and 30 months of age to see if the program reduces delays. The goal is to improve early detection and intervention for children who are often underdiagnosed.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Sickle Cell Caregiver Collaboration for Child Development (SCCCD), a home-based program combining the Parents as Teachers curriculum with occupational therapy
- What this could lead to
- If effective, this program could help children with sickle cell disease reach their developmental milestones and reduce learning or motor delays.
- What could go wrong
- This is an early-stage study with a small number of participants, so results may not apply broadly. The program requires caregiver time and commitment, and not all families may benefit equally.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Expected to start
-
Jul 2025
An estimate. Start dates often move.
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
6 to 31 months
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * All sickle cell disease genotypes will be included. Children will be eligible to participate until they reach 31 months of age (1 month over target evaluation). Exclusion Criteria: * Children will be excluded if the child has fragile health, a diagnosis associated with developmental deficit (not sickle cell disease), or the family is not English language proficient -because of limitations in alternative language assessment and intervention delivery.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Sickle cell disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63108, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Nonmyeloablative allogeneic peripheral blood mobilized hematopoietic precursor cell transplantation for severe congenital anemias including sickle cell disease (SCD) and B-Thalassemia
- Can an antioxidant supplement calm sickle cell blood cells?
- Can a softer transplant cure sickle cell disease?
- Mindfulness on your phone: a new test for sickle cell pain and sleep
- Urine and MRI: a new hope for spotting silent kidney injury in sickle cell kids?
- Could a common gene variant weaken bones early?